Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.
|Articles|June 7, 2018
- June 2018 (Vol. 39, No. 06)
- Volume 39
- Issue 6
Calming inflammation in common skin conditions
Author(s)Dermatology Times Staff, John Jesitus
Publishing new research findings has its benefits, but how physicians use that information and their personal experience in clinical practice can prove to be more insightful. In this table on page 98 of Dermatology Times June issue, we feature insights from three physicians who participated in the rapid-fire Q&A “60 Tips in 60 Minutes” from this year's Winter Clinical Dermatology Conference.
Advertisement
Articles in this issue
over 8 years ago
Melanoma diagnosis by physician or PA not always straightforwardover 8 years ago
Pulsed dye laser fails surgical scarsover 8 years ago
The acne supplementover 8 years ago
Cimzia receives positive CHMP opinion for plaque psoriasisover 8 years ago
FDA approves Tafinlar with Mekinist for melanomaover 8 years ago
SPSSCS names Donna Erb new presidentover 8 years ago
My employee has a needlestick injury. Now what?Advertisement
Related to this article
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
By week 36, combination therapy altered 482 proteins and 467 genes vs 140 and 16 with ixekizumab alone in exploratory TOGETHER-PsO data.
Advertisement
Advertisement
Trending on Dermatology Times
1
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Nonsteroidal Topicals Guide Special-Site Psoriasis Treatment Decisions
4
Severity, Response Timing, and Lab Monitoring in Alopecia Areata Care
5